homepage_cover_1

Firm of Choice
for the Most Difficult
Legal Issues

homepage_cover_2

Cross-Border Capabilities
with a China Edge

News

Fangda Advises Qyuns Therapeutics on its Exclusive License Agreement with Caldera Therapeutics for the Development and Commercialization on Qx030n

Insight

2024 Antitrust China Annual Review
With rising investigation/litigation risks, shifting regulatory priorities, and an increasing emphasis on fair competition, businesses must stay ahead of these changes to manage compliance effectively.

Awards & Rankings

Chambers & Partners Global Guide 2024
Band 1 Rankings

Chambers & Partners Greater China Region Guide 2024
Band 1 Rankings